Cargando…

Androgen deprivation therapy as backbone therapy in the management of prostate cancer

Androgen deprivation therapy (ADT) is well established as a backbone therapy for metastatic prostate cancer (mPCa), and both European and American guidelines emphasize the importance of maintaining ADT after progression to metastatic castration-resistant prostate cancer (CRPC). However, the use of A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merseburger, Axel S, Alcaraz, Antonio, von Klot, Christoph A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140029/ https://www.ncbi.nlm.nih.gov/pubmed/27942220 http://dx.doi.org/10.2147/OTT.S117176

Ejemplares similares

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
por: Merseburger, Axel S., et al.
Publicado: (2014)

An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
por: Merseburger, Axel S., et al.
Publicado: (2016)

Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management
por: Sountoulides, Petros, et al.
Publicado: (2013)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
por: Bagrodia, Aditya, et al.
Publicado: (2009)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
por: Saad, Fred, et al.
Publicado: (2021)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

Using a Further Planning MRI after Neoadjuvant Androgen Deprivation Therapy Significantly Reduces the Radiation Exposure of Organs at Risk in External Beam Radiotherapy of Prostate Cancer
por: Merten, Roland, et al.
Publicado: (2023)

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
por: Wadosky, Kristine M., et al.
Publicado: (2016)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
por: Abrahamsson, Per-Anders
Publicado: (2017)

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
por: Zhong, Shangwei, et al.
Publicado: (2022)

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
por: Terrisse, Safae, et al.
Publicado: (2022)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
por: Karl, Alexander, et al.
Publicado: (2009)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy
por: Moyad, Mark A, et al.
Publicado: (2016)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes
por: Ahmadi, Hamed, et al.
Publicado: (2014)

Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
por: Kalina, Jennifer L., et al.
Publicado: (2017)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
por: Iwamoto, Hiroaki, et al.
Publicado: (2022)

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy
por: von Klot, Christoph A., et al.
Publicado: (2017)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer
por: Golabek, Tomasz, et al.
Publicado: (2016)

Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy
por: Saylor, Philip J., et al.
Publicado: (2009)

Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
por: Lee, Sung Uk, et al.
Publicado: (2017)

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier
por: Etheridge, Tyler, et al.
Publicado: (2019)

Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes
por: Lazzerini, Pietro Enea, et al.
Publicado: (2020)

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling
por: Offermann, Anne, et al.
Publicado: (2016)

The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer
por: Gunner, Charlotte, et al.
Publicado: (2016)

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
por: Johnson, Matthew E., et al.
Publicado: (2012)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update
por: Hara, Noboru
Publicado: (2012)

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
por: Shore, Neal D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pp9ft0s1kbnkcattlmargsqqjb